Navigation Links
Global Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac
Date:10/8/2009

iCardiac Extends #1 Worldwide Market Position in Automated QT Studies

Rochester, New York (PRWEB) October 8, 2009 -- iCardiac Technologies, Inc., a global leader in advanced cardiac core lab services and QT analysis, announced today that an international pharmaceutical company has awarded iCardiac a comprehensive cardiac safety study. iCardiac will provide end-to-end study management, equipment deployment and scientific reporting, as well as advanced ECG analytics. The study will utilize iCardiac's Highly Automated QT(sm) and Dynamic QT beat-to-beat(sm) service offerings to dramatically improve study precision and reduce false positives and negatives.

"We are pleased that the industry's worldwide adoption of iCardiac's automated QT methods continues to accelerate," said Sasha Latypova, Executive Vice President. "With this contract award it is clear that the industry is transiting to more advanced methods for cardiac safety evaluation and that iCardiac is leading this transition."

In October 2005, the FDA introduced a new guidance for industry (ICH E14) requiring the evaluation of pro-arrhythmic potential of new drugs by measuring the QT segment of ECGs collected in clinical trials. The dissatisfaction among pharmaceutical developers with the poor precision, high rate of false positives/negatives and high cost of the "gold standard" manual or semi-automated QT measurements has lead to efforts toward providing more advanced cardiac safety analytics.

About iCardiac Technologies
iCardiac Technologies, Inc. is a technologically-differentiated global cardiac core lab providing the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies for Phase I through Phase IV studies, supported by expert scientific consultation, end-to-end project management, worldwide site and equipment logistics, 24/7 customer support and regulatory data submission. iCardiac's analysis services provide drug developers with more precise and cost-effective methods for ECG interval measurements, including Highly Automated QT, which is the market leading solution for automated evaluation of QT intervals for regulatory submissions. In addition, iCardiac provides Beyond QTsm, a suite of advanced ECG-based cardiac safety markers that have been accepted and used as a secondary end-point in regulatory approvals, and which delivers a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology and medical device companies. For more information, visit: www.icardiac.com.

# # #

Read the full story at http://www.prweb.com/releases/automated/tqt/prweb3005784.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
3. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
4. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
6. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
7. Jazz Pharmaceuticals to Present at UBS Global Life Sciences Conference
8. A Large-Scale Research Project by a Dutch Consortium Addressing a Global Problem
9. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
10. Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference
11. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... Crucial Data ... sites and study participants truly unified. TrialKit, a native mobile app, empowers investigators ... 11) research studies entirely on mobile devices. With TrialKit, clinical researchers can utilize ...
(Date:7/18/2017)... ... July 18, 2017 , ... ... Merck, a leading science and technology company, has implemented Genedata Biologics ™ ... therapeutic areas of Oncology, Immunology, and Neurodegenerative Diseases. , The need to systematically ...
(Date:7/18/2017)... Washington, DC (PRWEB) , ... July 18, 2017 ... ... for the Allotrope Framework, and has released the first phase of the Allotrope ... Bio-IT World’s Best Practices Awards were created to “not only elevate the critical ...
(Date:7/17/2017)... ... 17, 2017 , ... The Academy of Model Aeronautics (AMA) will host Aviation ... will take place from 9 a.m. to 2 p.m. at the International Aeromodeling Center ... , Aviation Adventure Day will be packed with entertaining activities for the entire family. ...
Breaking Biology Technology:
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft System ... over the next decade to reach approximately $14.21 billion by 2025. ... forecasts for all the given segments on global as well as ...
Breaking Biology News(10 mins):